Transine® has assembled an expert team to develop and exploit the groundbreaking SINEUP® technology. SINEUPs have a unique mechanism of action, amplifying protein expression by interacting with the natural cellular translation machinery. Transine has exclusive rights to commercialise the platform across the breadth of its applications, including in non-therapeutic fields. Our team is passionate about harnessing the potential of the SINEUP platform to benefit patients with serious diseases.
Jan has more than 20 years’ experience of building cross functional teams to drive delivery of innovative technologies. He has built platforms and played a leadership role in the commercialisation of therapeutics across small molecule, biopharmaceutical and gene therapy modalities. Jan joined Transine Therapeutics from Freeline Therapeutics where he was start-up CEO then Chief Development Officer overseeing deployment of a novel AAV platform and a rapidly growing clinical-phase portfolio. Prior to this Jan spent close to 20 years at GSK in multiple senior roles spanning from Discovery to Manufacturing environments, latterly overseeing the establishment of the Cell & Gene Therapy platform unit where he played a pivotal role in the commercialisation of Strimvelis, the first ex-vivo gene therapy to receive an EU Marketing Authorisation Application. He has served on multiple advisory boards in the CMC and regulatory space, playing a significant role in the shaping of the Cell and Gene therapy field. Jan holds an MA in Chemistry and a PDhil. in Biological Chemistry from Oxford University.
Anuj has nearly 20 years’ experience working across the life science sector. Prior to joining Transine, he was CEO of Zarodex Therapeutics, a seed funded immunology biotech, and CBO of TopiVert Pharma, a clinical stage ophthalmology company. Anuj started his pharmaceutical career with EUSA Pharma in 2009 where he headed up corporate development up to the sale of the company to Jazz Pharmaceuticals for $700m in 2012. He stayed on with Jazz as VP Business Development until 2018. During his time at Jazz and EUSA, Anuj gained valuable experience leading a variety of transactions in multiple geographies, including the $1bn acquisition of Gentium, in addition to operational assignments which included the launch of an oncology drug in the US. Prior to his pharmaceutical career, Anuj spent 5 years in equity research and investment banking with Bear Stearns, HSBC and J.P. Morgan covering European healthcare. Anuj holds a BSc in Chemistry from the University of Copenhagen and a PhD in Chemical Engineering from the University of Cambridge.
Madeleine joins Transine Therapeutics with over 20 years’ experience in biopharmaceutical research and development, and programme and portfolio management. Previously working for BioVex, GSK, MedImmune, MRC, Autolus, Crescendo and Cellinta, Madeleine has held increasingly senior programme management positions with vast experience in building and leading high performing matrix teams from discovery to clinical stage. Alongside programme management, Madeleine also brings significant alliance and operational management experience to Transine. Madeleine holds a PhD in Molecular Virology from the University of Edinburgh and is PMP® certified.
Andy has more than 20-years’ experience in drug discovery and early development, driving programmes from inception, though candidate selection and into clinical development in both internally and externally resourced paradigms. Andy joined in 2022 from NodThera, where he led translational efforts on multiple molecules which entered phase 1 for indications related to innate immunity, including neuroinflammation. Prior to this, Andy led the Neuroscience Discovery group at MedImmune/AstraZeneca, Cambridge, UK which delivered several protein therapeutic candidates into the clinic for neurodegeneration and pain. As a co-founder of Transpharmation, a boutique CRO was born which works with academic, biotech and pharma clients to deliver bespoke in vivo model solutions. At GSK, Andy worked on multiple projects, leading cross functional teams targeting neurological and pain indications from idea through to phase 2. Andy holds a PhD in neuropharmacology from the University of Birmingham.